Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the DietInduced Obesity Rat Model be Important in Liver Metabolism?

Objective: The aim of this study was to evaluate the contribution of sitagliptin, which is used in the treatment of type 2 diabetes mellitus due to its insulinotropic effects, to the levels of glucagon-like peptide-1 (GLP-1) expressed in many systemic tissues in obesity, in liver, skeletal muscle, a...

Full description

Bibliographic Details
Published in:	Experimed
Main Authors:	Cem Horozoğlu, Serkan Gürgül, Gülper Nacarkahya, Neslihan Cevik
Format:	Article
Language:	English
Published:	Istanbul University Press 2024-12-01
Subjects:	sitagliptin glp-1 obesity liver metabolism glp1r
Online Access:	https://dergipark.org.tr/en/download/article-file/4282885

Similar Items

GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity
by: Vijay Kumar
Published: (2025-07-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
by: Qiyuan Keith Liu
Published: (2024-07-01)

Berberine enhances the function of db/db mice islet β cell through GLP-1/GLP-1R/PKA signaling pathway in intestinal L cell and islet α cell
by: Wenbin Wu, et al.
Published: (2023-07-01)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
by: Lee SP, et al.
Published: (2019-06-01)

Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
by: Sudhir Pandey, et al.
Published: (2023-06-01)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
by: Stav Brown, et al.
Published: (2024-09-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
by: Miodrag Janić, et al.
Published: (2024-12-01)

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01)

Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice
by: Dawood Khan, et al.
Published: (2022-11-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
by: Tohada M. AL-Noshokaty, et al.
Published: (2025-06-01)

Geniposide Ameliorated Dexamethasone-Induced Cholesterol Accumulation in Osteoblasts by Mediating the GLP-1R/ABCA1 Axis
by: Yizhou Zheng, et al.
Published: (2021-12-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
by: Leigh Perreault, et al.
Published: (2024-06-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
by: Ioanna Daniilopoulou, et al.
Published: (2022-02-01)

GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death
by: Wu Li, et al.
Published: (2024-12-01)

Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea
by: Florencia Ziemke, et al.
Published: (2025-09-01)

Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities
by: Yang Xie, et al.
Published: (2023-09-01)

TXNIP reduces pro-proliferation effect of GLP-1 on mouse islet β cells
by: ZHANG Wen-ting, WANG Jin, YUE Ji-ping, JIN Wen-wen, ZHANG Zhi-nan, JIAO Xiang-ying
Published: (2020-08-01)

Analogos de GLP1: marcando nuevas rutas en el manejo de la diabetes
by: Luz Angela Casas Figueroa
Published: (2022-06-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
by: Velimir Altabas, et al.
Published: (2025-06-01)

Reduced GLP-1R availability in the caudate nucleus with Alzheimer’s disease
by: Emma Barrett, et al.
Published: (2024-06-01)

Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice
by: Christoffer Clemmensen, et al.
Published: (2015-02-01)

Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice
by: Seun Akindehin, et al.
Published: (2024-05-01)

Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures
by: Smriti Jain, et al.
Published: (2024-09-01)

Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs
by: Sandra Christensen, et al.
Published: (2024-09-01)

Assessing GLP-1 RAs in Diabetic Gastroparesis: A Literature Review
by: Jacob Itkin, et al.
Published: (2025-06-01)

Fasting GLP-1 Levels in Women with PCOS and CAH
by: Robeva R., et al.
Published: (2024-12-01)

Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment
by: Junichiro SATO, et al.
Published: (2025-03-01)

GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity
by: Pablo Arrona-Cardoza
Published: (2025-08-01)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
by: Fatemeh Taktaz, et al.
Published: (2024-07-01)

The VIP/VPAC1R Pathway Regulates Energy and Glucose Homeostasis by Modulating GLP-1, Glucagon, Leptin and PYY Levels in Mice
by: Daniel Sanford, et al.
Published: (2022-03-01)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
by: Rasmus Stenlid, et al.
Published: (2023-11-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
by: Feng Jia Nuo, et al.
Published: (2024-08-01)

Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
by: Shikha Patel, et al.
Published: (2025-08-01)